Welcome to our dedicated page for Pavmed news (Ticker: PAVM), a resource for investors and traders seeking the latest updates and insights on Pavmed stock.
PAVmed Inc. (NASDAQ: PAVM) generates news across medical devices, diagnostics, and digital health, reflecting its role as a diversified, commercial-stage medical technology company. Its news flow often covers developments at the parent company level as well as at its subsidiaries, Lucid Diagnostics Inc. and Veris Health Inc., which focus on cancer prevention diagnostics and digital cancer care.
Investors following PAVM news can expect updates on corporate actions, such as the announced 1-for-30 reverse stock split intended to help the company meet Nasdaq’s minimum bid price requirement and maintain its listing on the Nasdaq Capital Market. Company communications also highlight business updates, quarterly financial results, and information on balance sheet and capital structure decisions, often furnished through press releases and Form 8-K filings.
News related to Lucid Diagnostics, a subsidiary of PAVmed, frequently focuses on the commercialization and clinical performance of the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device. Recent announcements have described large real-world datasets on non-endoscopic esophageal precancer detection, Medicare coverage processes, and participation in medical and investor conferences.
Updates involving Veris Health typically center on the Veris Cancer Care Platform and its deployment in clinical settings. For example, PAVmed and Veris have reported the launch of the commercial phase of a long-term strategic partnership with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, focused on enhancing personalized cancer care for patients undergoing systemic cancer therapy.
This PAVM news page brings together these types of announcements, allowing readers to track financial disclosures, technology and platform milestones, regulatory and reimbursement developments, strategic partnerships, and corporate governance actions over time.
Lucid Diagnostics (NASDAQ: LUCD) closed an underwritten registered direct offering of 18,000,000 common shares at $1.00 per share, generating approximately $18 million in gross proceeds on April 24, 2026.
The offering was anchored by a $15 million investment from a fundamental institutional investor with support from a large existing shareholder. Net proceeds are intended for working capital and general corporate purposes.
Lucid Diagnostics (Nasdaq: LUCD) priced an underwritten registered direct offering of 18,000,000 common shares at $1.00 per share, anchored by a $15 million institutional investment, with gross proceeds of approximately $18 million. The company intends to use net proceeds for working capital and general corporate purposes.
The offering is expected to close on or about April 24, 2026, subject to customary conditions. Canaccord Genuity and BTIG are joint bookrunners. The offering is made under a Form S-3 shelf registration declared effective March 26, 2026.
Lucid Diagnostics (Nasdaq: LUCD) announced that CEO and chairman Lishan Aklog, M.D., will take part in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026 at 10:15 AM EDT.
The event will be webcast live and a replay will be archived on the company's Investor Relations website for 30 days.
PAVmed (LUCD) appointed Joseph Virgilio as Senior Vice President and Chief Business Officer, Medical Devices, and relaunched its medical device portfolio on April 2, 2026. The company formed a new subsidiary, Octeris, and executed a definitive license with Duke University for multi-modality endoscopic esophageal imaging.
The portfolio includes the PortIO implantable intraosseous vascular access device and the Duke-licensed endoscopic imaging technology; Virgilio will also lead subsidiaries PortIO Inc. and Octeris Inc.
PAVmed (NASDAQ: PAVM) reported Q4 and full-year 2025 results and a business update on March 30, 2026. Highlights include a $30M Series D preferred offering, a $15M senior secured note, elimination of outstanding convertible securities, relaunch of medical devices, Veris commercialization with OSU-The James, and Lucid Diagnostics progress on EsoGuard.
Financials: Q4 GAAP net loss attributable to common stockholders was $(1.8M) and non-GAAP adjusted loss was $(0.9M); cash and equivalents were $1.5M as of December 31, 2025.
Lucid Diagnostics (Nasdaq: LUCD) reported 4Q25 EsoGuard revenue of $1.5M from 3,664 tests and full-year revenue of $4.706M. The company secured a national VA contract covering ~170 VA medical centers with Medicare-aligned pricing of $1,938 and reported positive real-world data showing 95% technical success and 95% of procedures under two minutes. Cash and equivalents were $34.7M at year-end. GAAP net loss was $16.3M for 4Q25 (EPS $(0.12)) and non-GAAP adjusted loss was $12.6M.
PAVmed (NASDAQ: LUCD) will hold a Fourth Quarter and Full Year 2025 business update conference call and webcast on March 30, 2026 at 8:30 AM ET. Management will review operations, growth strategy and fourth quarter 2025 financial results.
The webcast will be available in the investor relations section at pavmed.com and a telephone dial-in is provided for U.S. and international callers. A replay will be accessible on the company website for 30 days.
Lucid Diagnostics (Nasdaq: LUCD) will host a fourth quarter and full year 2025 business update conference call and webcast on March 26, 2026 at 8:30 AM ET. The call will feature CEO Lishan Aklog and CFO Dennis McGrath discussing operations and Q4 2025 financial results.
The webcast and 30-day replay will be available in the investor relations section at luciddx.com; dial-in numbers are provided for U.S. and international callers.
PAVmed (Nasdaq: PAVM) closed a Series D Convertible Preferred Stock financing of $30 million and a $15 million senior secured note (maturing Feb 2029), using proceeds to redeem all prior convertible securities and materially strengthen liquidity.
The Series D includes warrants exercisable for up to an additional $30 million upon publication of a positive EsoGuard Medicare LCD; a stockholder vote to convert Series D at $6.50 per share will be held no later than April 30, 2026.
Lucid Diagnostics (Nasdaq: LUCD) was awarded a contract by the U.S. Department of Veterans Affairs on January 21, 2026 to supply its EsoGuard® Esophageal DNA Test through the VA Federal Supply Schedule.
The contract expands access to esophageal precancer testing across the VA system serving more than 9 million enrolled veterans, uses a single national VA procurement framework, and sets pre-negotiated pricing that matches the established Medicare payment rate as determined by CMS.
Lucid said the selection reflects the clinical evidence for EsoGuard and plans to work with the VA and other integrated health systems to adopt the test into clinical practice.